Here are the 10-K annual reports from Clene Inc. Warrant (CLNNW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CLNNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLNNW filings page.
Clene Inc. is a clinical-stage pharmaceutical company focused on clean-surfaced nanocrystal (CSN) therapeutics targeting neurodegenerative diseases such as ALS, multiple sclerosis, and Parkinson’s disease. Its lead asset, CNM-Au8, is an orally delivered gold nanocrystal suspension designed to boost cellular energy and reduce oxidative stress.
The company reports extensive preclinical and Phase 1–2 data suggesting neuroprotective, remyelinating, and biomarker effects, including NAD+/ATP increases and reduced neurofilament light chain in ALS. Clene is pursuing an accelerated approval pathway for CNM-Au8 in ALS, aiming to submit an NDA by June 2026 and planning a Phase 3 RESTORE-ALS trial as a confirmatory study, subject to funding.